Division of Teva Pharmaceutical Industries Ltd.
Latest From Actavis Generics
As the US generics market continues to experience turbulence, the industry’s largest players are adopting a wide range of strategies to cope with the uncertainty as signs of stabilization begin to emerge.
Teva’s Actavis has lost the patent battle over osteoarthritis drug Pennsaid 2% due to a lack of “clear and convincing evidence” and “unpersuasive arguments” over obviousness.
An attempt by Accord, Actavis, Apotex, Kabi and Mylan to overturn a US patent protecting Sanofi’s Jevtana cabazitaxel cancer drug until 2021 has failed. And claims in a patent running until 2031 could yet return to haunt the generics firms.
Teva has registered a further impairment of almost $500m, largely linked to the value of assets acquired when it took over Actavis in 2016. Meanwhile, sales slid by 15% to $4.3bn in the first quarter.
- Generic Drugs
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Teva Pharmaceutical Industries Ltd.
- Senior Management
- Contact Info
Phone: (905) 814-1820
6733 Mississauga Road
Mississauga, L5N 6J5
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.